Cargando…

Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China

BACKGROUND: To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society. METHODOLOGY/PRINCIPAL FINDINGS: A mathematical model was developed by incorporating the clinical trial data and Chin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Bin, Wilson, Alisa, Wang, Fang-fang, Wang, Su-li, Wallace, Daniel J., Weisman, Michael H., Lu, Liang-jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467255/ https://www.ncbi.nlm.nih.gov/pubmed/23056637 http://dx.doi.org/10.1371/journal.pone.0047373

Ejemplares similares

Cost-Effectiveness Modelling of Sequential Biologic Strategies for the Treatment of Moderate to Severe Rheumatoid Arthritis in Finland
por: Puolakka, K, et al.
Publicado: (2012)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies
por: Wang, Qin, et al.
Publicado: (2021)

Total knee arthroplasty treatment of rheumatoid arthritis with severe versus moderate flexion contracture
por: Yan, Denglu, et al.
Publicado: (2013)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States
por: Claxton, Lindsay, et al.
Publicado: (2016)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
por: Zhou, Ting, et al.
Publicado: (2021)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values
por: Dunlop, William, et al.
Publicado: (2013)

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
por: Fournier, Marie, et al.
Publicado: (2019)

Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis
por: Song, Guanhua, et al.
Publicado: (2019)

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2015)

Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
por: Bessette, Louis, et al.
Publicado: (2023)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Chemokines in Rheumatoid Arthritis
por: Koch, Alisa
Publicado: (2000)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
por: Thudium, Christian S., et al.
Publicado: (2020)

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
por: Bessette, Louis, et al.
Publicado: (2017)

Treatment satisfaction with rheumatoid arthritis in patients with different disease severity and financial burden: A subgroup analysis of a nationwide survey in China
por: Li, Hong-Bin, et al.
Publicado: (2020)

Genetics of rheumatoid arthritis susceptibility, severity, and treatment response
por: Viatte, Sebastien, et al.
Publicado: (2017)

Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China
por: Jiang, Nan, et al.
Publicado: (2020)

Application of nanomaterials in the treatment of rheumatoid arthritis
por: Zheng, Miaomiao, et al.
Publicado: (2021)

Hydrogels for the treatment of rheumatoid arthritis
por: Yi, Jiafeng, et al.
Publicado: (2022)

Vasculogenesis in rheumatoid arthritis
por: Szekanecz, Zoltán, et al.
Publicado: (2010)

The Treatment of Rheumatoid Arthritis
Publicado: (1929)

Treatment of Rheumatoid Arthritis
Publicado: (1892)

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
por: Diamantopoulos, Alex, et al.
Publicado: (2014)

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Joensuu, Jaana T., et al.
Publicado: (2015)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
por: Navarro, F., et al.
Publicado: (2020)

Effective rheumatoid arthritis treatment requires comprehensive management strategies
por: Boomershine, Chad S
Publicado: (2009)

Toward Overcoming Treatment Failure in Rheumatoid Arthritis
por: Wang, Zhuqian, et al.
Publicado: (2021)

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
por: Soriano, Enrique R, et al.
Publicado: (2018)

Indirect costs of rheumatoid arthritis
por: Raciborski, Filip, et al.
Publicado: (2015)

Chinese registry of rheumatoid arthritis: IV. Correlation and consistency of rheumatoid arthritis disease activity indices in China
por: Song, Xing, et al.
Publicado: (2021)

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
por: Wehler, Elizabeth, et al.
Publicado: (2019)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
por: Smolen, Josef S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c50i2ie79o74pkh8gunvhrrqo3